

exchange between eucarvone and deuterioethanol at room temperature (oximation conditions). Our findings indicate clearly that *three* hydrogens from eucarvone are replaceable by deuterium under these conditions.³ Since eucarvone in the monocyclic form has only two readily replaceable hydrogens, and in view of the results mentioned above, the intervention of the bicyclic ketone VI and/or its anion seems probable.

If there is any of the bicyclic ketone VI normally in equilibrium with eucarvone, the amount is small (less than 1%) as determined from the ultraviolet spectrum of eucarvone, λ_{\max} 302 m μ (log ϵ 3.82), only slight end absorption near 230 m μ .⁴

It seems likely that other transformation products of eucarvone (including some previously described) also possess the bicyclic nucleus. We are investigating some of these cases at present.




Fig. I.

(3) Determined by isolation of the eucarvone, combustion, and assay of the D_2O - H_2O mixture by the falling drop method: A. S. Keston, D. Rittenberg and R. Schoenheimer, *J. Biol. Chem.*, **122**, 227 (1942).

(4) All ultraviolet spectra were determined in 95% ethanol.

NOYES CHEMICAL LABORATORY
DEPARTMENT OF CHEMISTRY AND
CHEMICAL ENGINEERING
UNIVERSITY OF ILLINOIS
URBANA, ILLINOIS

E. J. COREY
H. J. BURKE

RECEIVED AUGUST 26, 1954


GLYCINE RIBOTIDE INTERMEDIATES IN THE *de novo* SYNTHESIS OF INOSINIC ACID¹

Sir:

Pigeon liver extracts carry out the synthesis of two glycine-containing aliphatic ribotides which appear to be intermediates in the *de novo* synthesis

(1) This investigation was aided by grants from the U. S. Public Health Service, National Institutes of Health, The Elisabeth Severance Prentiss Foundation and Eli Lilly and Company.

of inosinic acid. Compound I has been tentatively assigned the following basic structure:



The second compound (II) appears to differ from I by the presence of a formyl group.

The synthesis of I by pigeon liver extracts, passed through a Dowex-1-chloride column and dialyzed, requires ATP², R-5-P, glycine and glutamine (Table I). This reaction is measured by the conversion of glycine-1-C¹⁴ to a radioactive compound which does not lose C¹⁴ when treated with ninhydrin. I is eluted from a Dowex-1-formate column with 0.05 M ammonium formate at pH 6.5.

TABLE I

REQUIREMENTS FOR THE SYNTHESIS OF I

Additions: 20 mg. of an extract of pigeon liver acetone powder treated with Dowex-1 chloride,³ dialyzed *versus* 0.05 M K_2HPO_4 and lyophilized. 1.5 μM . ATP, 5 μM . Na phosphocreatine, 0.05 ml. 1:2 aqueous rabbit muscle extract dialyzed against water, 6.4 μM . MgCl_2 , 5 μM . glycine-1-C¹⁴, 5 μM . glutamine, 2.5 μM . K-ribose-5-phosphate, 30 μM . K_2HPO_4 (final quantity); vol. 0.67 ml.; time 20 min., 38°, air.

R-5-P	+	-	+	+	
Glutamine	+	+	-	+	
ATP ^a	+	+	+	-	
μM . C ¹⁴ glycine	Expt. 1	0.25	0.00	0.01	...
incorporated	Expt. 2	0.15	0.01	0.02	0.02

^a Includes regenerating system of creatine phosphokinase (muscle extract) and phosphocreatine.

II is eluted from a Dowex-1-formate column with 0.05 M ammonium formate at pH 5.0. This compound possesses a characteristic acid-labile (0.1 N HCl, 100°, 15 min.) formyl group which allows its direct determination. II can be labeled by either C¹⁴ glycine or C¹⁴ formate, but not by C¹⁴O₂. The requirements for the synthesis of II are: ATP, R-5-P, glycine, glutamine, formate and boiled extract of liver. The boiled extract can be completely replaced by leucovorin or by tetrahydrofolic acid.³ Some of these requirements are shown in Table II.

TABLE II

REQUIREMENTS FOR THE SYNTHESIS OF II

Conditions as in Table I plus the following: 0.2 mg. Ca leucovorin or tetrahydrofolic acid (neutralized), 2.5 μM . C¹⁴ Na-formate and non-radioactive glycine; time 30 min.

Experiment	1				2			
FAH ₄	+	-	-	-	-	-	-	-
CF	-	+	-	+	+	+	+	+
R-5-P	+	+	+	+	-	+	+	+
Glutamine	+	+	+	+	+	-	+	+
Glycine	+	+	+	+	+	+	+	-
Hydrolyzable C ¹⁴ -formyl, μM .	0.35	0.37	0.016	0.49	0.12	0.08	0.04	

Under conditions for synthesis of II, small quantities of I are found by chromatographic anal-

(2) Abbreviations: adenosine triphosphate, ATP; D-ribose-5-phosphate, R-5-P; leucovorin (*dl* form of citrovorum factor), CF; tetrahydrofolic acid, FAH₄.

(3) G. R. Greenberg, *THIS JOURNAL*, **76**, 1458 (1954).

